SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that it will collaborate with Baltimore-based Intralytix, Inc. in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
Newsroom
Friday, 03 July 2015